Research programme: anti-Hsp90 antibodies - Biotecnol/Pharmis
Latest Information Update: 14 Jun 2012
At a glance
- Originator Biotecnol SA; Pharmis Biofarmaceutica
- Class Antibodies
- Mechanism of Action HSP90 heat-shock protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Jun 2012 Preclinical development is ongoing Portugal
- 30 May 2007 Preclinical trials in Cancer in Portugal (Parenteral)